GlassScriptPhysician profile
Rani Wilson
NPI 1699303875
$3,192.90
in general payments reported to CMS, 2019-2025
20 companies · $818 in 2025
The $818 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $508 · 2023: $1,369 · 2024: $499 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,685.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $673.23 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Tris Pharma INC | $484.95 | 2023 | Dyanavel Xr |
| Depuy Synthes Sales INC. | $333.83 | 2024-2025 | Trialtis, Speed Triad, Symphony |
| Otsuka America Pharmaceutical, INC. | $270.00 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $260.13 | 2022-2024 | |
| Corium, LLC | $214.97 | 2022-2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $131.55 | 2022-2023 | Hetlioz, Fanapt |
| Integra Lifesciences Corporation | $128.88 | 2023 | Biofix, Biodoptix, Biodrestore |
| Lundbeck LLC | $126.27 | 2022-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.01 | 2022-2023 | |
| Neos Therapeutics, LP | $71.62 | 2022-2023 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $69.33 | 2022-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $66.30 | 2023-2024 | Invega Sustenna, Invega, Spravato |
| Sunovion Pharmaceuticals INC. | $55.71 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $53.38 | 2022-2023 | Austedo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $53.28 | 2025 | Erzofri Extended-Release |
| E.R. Squibb & Sons, L.L.C. | $52.44 | 2025 | Cobenfy |
| Eisai INC. | $21.14 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.44 | 2022 | |
| Axsome Therapeutics, INC. | $15.44 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rani Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.